Translational control: A target for cancer therapy

Cancer Letters

Volumn 258, Issue 1, 2007, Pages 1-8

  Thumma, Saritha C ^a   Kratzke, Robert A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cap dependent; eIF4E; eIF4F; Translation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN INHIBITOR; RAPAMYCIN; RAPAMYCIN DERIVATIVE;

BLADDER CANCER; BREAST CANCER; CANCER; CANCER CELL; CANCER THERAPY; CHEMOSENSITIZATION; COLON CANCER; DRUG TARGETING; GENE CONTROL; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; SHORT SURVEY; TRANSLATION REGULATION; UTERINE CERVIX CANCER;

EUKARYOTA;

EID: 35348954728     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.08.022     Document Type: Review

References (76)

1. Lodish H.F. Translational control of protein synthesis. Annu. Rev. Biochem. 45 (1976) 39-72
2. Hershey J.W.B., and Merrick W.C. Pathway and mechanism of initiation of protein synthesis. In: Sonenberg N., Hershey J.W.B., and Merrick W.C. (Eds). Translational Control of Gene Expression (2000), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 33-88
3. Dever T.E. Gene-specific regulation by general translation factors. Cell 108 4 (2002) 545-556
4. Carpenter C.L., and Cantley L.C. Essentials of signal transduction. In: De-Vita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer principles and practice of oncology. 6th ed. (2001), JB Lippincott, Philadelphia 39-41
5. Gingras A.C., Raught B., and Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68 (1999) 913-963
6. Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L.W., and Sonenberg N. eIF4E-from translation to transformation. Oncogene 23 18 (2004) 3172-3179
7. Zimmer S.G., DeBenedetti A., and Graff J.R. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res. 20 3A (2000) 1343-1351
8. Gingras A.C., Raught B., and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15 7 (2001) 807-826
9. Gross J.D., Moerke N.J., von der Haar T., Lugovskoy A.A., Sachs A.B., McCarthy J.E., and Wagner G. Ribosome loading onto the mRNA cap is driven by conformational coupling between eIF4G and eIF4E. Cell 115 6 (2003) 739-750
10. De Benedetti A., and Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23 18 (2004) 3189-3199
11. Koromilas A.E., Lazaris-Karatzas A., and Sonenberg N. mRNAs containing extensive secondary structure in their 5′ noncoding region translate efficiently in cells over expressing initiation factor eIF-4E. EMBO J. 11 11 (1992) 4153-4158
12. Rhoads R.E., Joshi-Barve S., and Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: effects of mRNA discrimination, cellular growth rate, and oncogenesis. Prog. Nucl. Acid Res. Mol. Biol. 46 (1993) 183-219
13. Kevil C.G., De Benedetti A., Payne D.K., Coe L.L., Laroux F.S., and Alexander J.S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int. J. Cancer 65 6 (1996) 785-790
14. Kevil C., Carter P., Hu B., and DeBenedetti A. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 11 11 (1995) 2339-2348
15. Schmidt E.V. The role of c-myc in regulation of translation initiation. Oncogene 23 18 (2004) 3217-3221
16. Rosenwald I.B., Lazaris-Karatzas A., Sonenberg N., and Schmidt E.V. Elevated levels of cyclin D1 in response to increased expression of eukaryotic initiation factor 4E. Mol. Cell Biol. 13 12 (1993) 7358-7363
17. Rosenwald I.B., Kaspar R., Rousseau D., et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D at transcriptional and posttranscriptional levels. J. Biol. Chem. 270 36 (1995) 21176-21180
18. Rousseau D., Kaspar R., Rosenwald I., Gehrke L., and Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl. Acad. Sci. USA 93 3 (1996) 1065-1070
19. Zimmer S.G., and Graff J.R. The emerging role for the mRNA cap-binding protein, eIF-4E, in metastatic progression. In: Welch D.R. (Ed). Cancer Metastasis-Related Genes (2002), Kluwer Academic Publishers, Dordrecht, The Netherlands 247-265
20. Graff J.R., and Zimmer S.G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Metastasis 20 3 (2003) 265-273
21. Gingras A.C., Gygi S.P., Raught B., et al. Regulation of 4EBP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13 11 (1999) 1422-1437
22. Gingras A.C., Raught B., Gygi S.P., et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15 21 (2001) 2852-2864
23. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., and Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev. 12 4 (1998) 502-513
24. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98 18 (2001) 10314-10319
25. DeFatta R.J., Turbat-Herrera E.A., Li B.D., Anderson W., and De Benedetti A. Elevated expression of eIF-4E in confined early breast cancer lesions: possible role of hypoxia. Int. J. Cancer 80 4 (1999) 516-522
26. Zhong H., De Marzo A.M., Laughner E., Lim M., et al. Over expression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 22 (1999) 5830-5835
27. Kerekatte V., Smiley K., Hu B., et al. Int. J. Cancer 64 1 (1995) 27-31
28. Li B.D., Liu L., Dawson M., and De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79 12 (1997) 2385-2390
29. Scott P.A., Smith K., Poulsom R., De Benedetti A., Bicknell R., and Harris A.L. Differential expression of vascular endothelial growth factor mRNA vs. protein isoform expression in human breast cancer and relationship to elF-4E. Br. J. Cancer 77 12 (1998) 2120-2128
30. Li B.D., McDonald J.C., Nassar R., and De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann. Surg. 227 5 (1998) 756-76l
31. Li B.D., Gruner J.S., Abreo F., Johnson L.W., et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann. Surg. 235 5 (2002) 732-738
32. McClusky D.R., Chu Q., Yu H., Debenedetti A., et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann. Surg. 242 4 (2005) 584-590
33. Byrnes K., White S., Chu Q., Meschonat C., Yu H., et al. High eIF4E, VEGF, and micro vessel density in stage I to III breast cancer. Ann. Surg. 243 5 (2006) 684-690
34. Zhou S., Wang G.P., Liu C., and Zhou M. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer 6 (2006) 231
35. Nathan C.A., Sanders K., Abreo F.W., Nassar R., and Glass J. Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications. Cancer Res. 60 13 (2000) 3599-3604
36. Nathan C.A., Liu L., Li B.D., Abreo F.W., Nandy I., and De Benedetti A. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 15 (1997) 579-584
37. Nathan C.A., Franklin S., Abreo F.W., Nassar R., et al. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J. Clin. Oncol. 17 9 (1999) 2909-2914
38. Nathan C.A., Amirghahri N., Rice C., Abreo F.W., Shi R., and Stucker F.J. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope 112 12 (2002) 2129-2140
39. Nathan C.A., Franklin S., Abreo F.W., Nassar R., et al. Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Laryngoscope 109 8 (1999) 1253-1258
40. Nathan C.A., Amirghahari N., Abreo F., Rong X., et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 10 17 (2004) 5820-5827
41. Franklin S., Pho T., Abreo F.W., Nassar R., et al. Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. Arch. Otolaryngol. Head Neck Surg. 125 2 (1999) 177-182
42. Chapman A.D., and Kerr K.M. The association between atypical adenomatous hyperplasia and primary lung cancer. Br. J. Cancer 83 5 (2000) 632-636
43. Mori M., Rao S.K., Popper H.H., Cagle P.T., and Fraire A.E. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod. Pathol. 14 2 (2001) 72-84
44. Rosenwald I.B., Hutzler M.J., Wang S., Savas L., and Fraire A.E. Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 92 8 (2001) 2164-2171
45. Seki N., Takasu T., Mandai K., Nakata M., et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin. Cancer Res. 8 10 (2002) 3046-3053
46. Jacobson B.A., Alter M.D., Kratzke R.A., et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res. 66 8 (2006) 4256-4262
47. Melhem M.F., Meisler A.I., and Finley G.G. Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors. Cancer Res. 52 21 (1992) 5853-5864
48. Rosenwald I.B., Rhoads D.B., Callanan L.D., Isselbacher K.J., and Schmidt E.V. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc. Natl. Acad. Sci. USA 90 13 (1993) 6175-6178
49. Jones R.M., Branda J., and Johnston K.A. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol. Cell Biol. 16 9 (1996) 4754-4764
50. Rosenwald I.B., Chen J.J., Wang S., Savas L., London I.M., and Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 18 15 (1999) 2507-2517
51. Berkel H.J., Turbat-Herrera E.A., Shi R., and de Benedetti A. Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol. Biomarkers Prev. 10 6 (2001) 663-666
52. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., and Pandolfi P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10 5 (2004) 484-486
53. Mossafa H., Damotte D., Jenabian A., Delarue R., et al. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk. Lymphoma. 47 9 (2006) 1885-1893
54. Wang S., Rosenwald I.B., Hutzler M.J., et al. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am. J. Pathol. 155 1 (1999) 247-255
55. Matthews-Greer J., Caldito G., de Benedetti A., et al. eIF4E as a marker for cervical neoplasia. Appl. Immunohistochem. Mol. Morphol. 13 4 (2005) 367-370
56. Matthews-Greer J., DeBenedetti A., Tucker A., et al. A model for angiogenesis in HPV-medicated cervical neoplasia. J. Appl. Res. 2 (2002) 63-73
57. Lee J.W., Choi J.J., Lee K.M., Choi C.H., et al. eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum. Pathol. 36 11 (2005) 1197-1203
58. Dickinson A.J., Fox S.B., Persad R.A., Hollyer J., Sibley G.N., and Harris A.L. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br. J. Urol. 74 6 (1994) 762-766
59. Bochner B.H., Cote R.J., Weidner N., Groshen S., Chen S.C., Skinner D.G., and Nichols P.W. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst. 87 21 (1995) 1603-1612
60. Jaeger T.M., Weidner N., Chew K., Moore D.H., Kerschmann R.L., Waldman F.M., and Carroll P.R. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol. 154 1 (1995) 69-71
61. O'Brien T., Cranston D., Fuggle S., Bicknell R., and Harris A.L. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 55 3 (1995) 510-513
62. Crew J.P., O'Brien T.S., and Harris A.L. Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Cancer Metastasis Rev. 15 2 (1996) 221-230
63. Crew J.P., Fuggle S., Bicknell R., Cranston D.W., de Benedetti A., and Harris A.L. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br. J. Cancer 82 1 (2000) 161-166
64. De Benedetti A., Joshi-Barve S., Rinker-Schaeffer C., and Rhoads R.E. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. Mol. Cell Biol. 11 11 (1991) 5435-5445
65. Rinker-Schaeffer C.W., Graff J.R., De Benedetti A., Zimmer S.G., and Rhoads R.E. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int. J. Cancer 55 5 (1993) 841-847
66. Graff J.R., Boghaert E.R., De Benedetti A., Tudor D.L., Zimmer C.C., Chan S.K., and Zimmer S.G. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int. J. Cancer 60 2 (1995) 255-263
67. DeFatta R.J., Nathan C.A., and De Benedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 110 6 (2000) 928-933
68. Graff J.R., Konicek B.W., Lynch R.L., Vincent T.M., et al. Depleting eIF4E expression with a novel eIF4E targeted antisense oligonucleotide suppresses eIF4E expression and human xenograft tumor growth without overt toxicity. Proc. Amer. Assoc. Cancer Res. 46 (2005)
69. Hara K., Yonezawa K., and Kozlowski M.T. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 272 42 (1997) 26457-26463
70. Huang S., and Houghton P.J. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3 4 (2003) 371-377
71. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 37 1 (2005) 19-24
72. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 4 5 (2003) 343-348
73. Guba M., von Breitenbuch P., Steinbauer M., and Koehl G. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 2 (2002) 128-135
74. Luan F.L., Ding R., Sharma V.K., Chon W.J., Lagman M., and Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 63 3 (2003) 917-926
75. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten mice. Proc. Natl. Acad. Sci. USA 98 18 (2001) 10320-10325
76. Moerke N.J., Aktas H., Chen H., Cantel S., et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128 2 (2007) 257-267